George Cox has been named to the board of the Frederick (Md.) Innovative Technology Center, after serving the incubator as a member of its client selection committee.
Cox represents several biotechnology and pharmaceutical companies as an associate with the Baltimore law firm Miles and Stockbridge, where he is also a member of the firm’s life sciences team, focusing on intellectual property and business law.
Cox previously accumulated almost 20 years of biomedical research experience, as a senior staff fellow at the National Cancer Institute, and earlier as an assistant professor of pharmacology and molecular and cell biology at the Uniformed Services University of the Health Sciences.
John McKearn has been named a venture partner at RiverVest Venture Partners, a St. Louis venture capital firm focused on financing life sciences companies.
McKearn previously served as CEO of Kalypsys, a privately held biotechnology company in San Diego, for which he raised more than $150 million in private equity during his three years with the company. He joined Kalypsys in 2003 as chief scientific officer, and was promoted two years later to CEO.
Earlier he served as head of research for Pharmacia (since merged into Pfizer) and a predecessor company, GD Searle. Before joining Searle, he held a pharmaceutical R&D position at DuPont.
McKearn serves on the boards of IDM Pharma, formerly Epimmune, and for Keel Pharmaceuticals. He holds a PhD in immunology from the University of Chicago and a BSci in biology from Northern Illinois University.
Traversa Therapeutics, a 2006 spinout of the University of California-San Diego developing RNAi-based screening tools and therapeutics, has named Barry Toyonaga as vice president of business development.
Toyonaga has previously held positions within the corporate venture arm of Johnson & Johnson, and has served as CEO of Ontogen. Toyonaga has been a visiting research scientist at The Scripps Research Institute, the California Institute of Technology, and Yale University School of Medicine. He was a postdoc at the Ontario Cancer Institute/Princess Margaret Hospital and received a PhD in physical organic chemistry from the University of Toronto.